<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56966">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01821833</url>
  </required_header>
  <id_info>
    <org_study_id>INST 1211</org_study_id>
    <secondary_id>NCI-2013-00443</secondary_id>
    <nct_id>NCT01821833</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel</brief_title>
  <official_title>A Pilot Randomized, Placebo Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Mexico Cancer Care Alliance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alliance Healthcare Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New Mexico Cancer Care Alliance</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized pilot clinical trial studies omega-3 fatty acid in treating pain in patients
      with breast or ovarian cancer receiving paclitaxel. Omega-3 fatty acid may help lessen pain
      caused by paclitaxel in patients with breast or ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine whether omega-3 fatty acids can prevent or ameliorate paclitaxel associated
      pain syndrome (P-APS) in cancer patients.

      SECONDARY OBJECTIVES:

      I. To determine whether omega-3 fatty acids can prevent development of peripheral
      neuropathy.

      II. To assess tolerability of omega -3 fatty acids in this setting. III. To compare quality
      of life (QOL) with omega 3 fatty acids supplementation versus placebo.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive omega-3 fatty acid orally (PO) once daily (QD) or twice daily (BID)
      for 12 weeks.

      ARM II: Patients receive placebo PO QD or BID for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Mean severity of pain</measure>
    <time_frame>Up to 1 month after completion of therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences between groups will analyzed via t-tests or Wilcoxon rank-sum tests as appropriate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of pain or relief</measure>
    <time_frame>Up to 1 month after completion of therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fisher's exact test will be used for the incidence variable with 95% confidence intervals.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Neoplasm</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Arm I (omega-3 fatty acid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive omega-3 fatty acid PO QD or BID for 12 weeks. Patients complete quality-of-life assessment form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO QD or BID for 12 weeks. Patients complete quality-of-life assessment form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega-3 fatty acid</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (omega-3 fatty acid)</arm_group_label>
    <other_name>fish oil</other_name>
    <other_name>n-3 fatty acid</other_name>
    <other_name>O3FA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (omega-3 fatty acid)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>Quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients have a diagnosis of breast cancer or ovarian cancer

          -  Patients are scheduled to receive weekly paclitaxel at 70-90 mg/m^2 for a minimum of
             2 months; 3 out of 4 weeks is allowed

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2

          -  Patients must not have taken omega-3-fatty acid supplements within the past 1 month
             prior to registration and must agree to refrain from use of omega- 3 fatty acid
             supplements from sources outside the study

          -  Patients must not be on nonsteroidal anti-inflammatory drugs (NSAIDS) or aspirin for
             at least 1 week prior to registration; NSAIDS or aspirin are allowed after enrollment

          -  Patients must not have received any other analgesics (opiates and tramadol) 1 week
             prior to registration; analgesics (opiates and tramadol) are allowed after enrollment

          -  Patients must have the ability to complete questionnaires by themselves or with
             assistance

          -  Patients must not be on anticoagulation medication (heparin/ warfarin) within 28 days
             prior to registration, because of increased risk of bleeding

          -  Concurrent treatment with carboplatin +/- bevacizumab is allowed

          -  Concurrent treatment with human epidermal growth factor receptor (Her2 neu) targeted
             therapy is allowed

        Exclusion Criteria:

          -  Known allergy to omega 3 fatty acids, fish or shellfish

          -  Pre-existing diagnosis of peripheral neuropathy

          -  Diagnosis of fibromyalgia

          -  Concurrent planned neutrophil colony stimulating factor therapy

          -  Prior exposure to paclitaxel within the last 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zoneddy Dayao</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie Parks, RN</last_name>
    <phone>505-925-0390</phone>
    <email>vparks@salud.unm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoneddy R. Dayao, MD</last_name>
      <phone>505-925-5490</phone>
      <email>zdayao@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Zoneddy R. Dayao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presbyterian Medical Group</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Burman, RN</last_name>
      <phone>505-559-6113</phone>
    </contact>
    <investigator>
      <last_name>Bernard Agbemadzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.unm.edu</url>
    <description>University of New Mexico Cancer Center</description>
  </link>
  <link>
    <url>http://www.nmcca.org</url>
    <description>New Mexico Cancer Care Alliance</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 5, 2013</lastchanged_date>
  <firstreceived_date>March 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>omega-3</keyword>
  <keyword>fatty acids</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>acute pain syndrome</keyword>
  <keyword>peripheral neuropathy</keyword>
  <keyword>chemotherapy induced neuropathy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
